Mehta Analysis: The New Decade Is Sure to Transform Biopharma Globally
But Are Industry Leaders Keeping Pace?
Executive Summary
Industry has the tools to bring more and far better treatments to more people faster than ever, with much lower R&D cost and very little selling needed for these targeted therapies – a perfect prescription for slashing prices for global access while preserving profits, argues Viren Mehta of Mehta Partners LLC.